Abstract
Erectile dysfunction (ED) is often associated with cardiovascular disease (CVD) and the risk of sildenafilinduced orthostatic hypotension (OH) in subjects with CVD is a matter of concern. We describe our experience in using the tilt test (TT) with continuous plethysmography to evaluate the occurrence of OH in patients with CVD and ED after a test dose of sildenafil. When sildenafil was added on top of their usual pharmacological treatment two patients out of 32 (6.2%) developed asymptomatic OH, with a maximum blood pressure fall of 40/20 mm Hg. The low prevalence and modest clinical relevance of OH in our high-risk population coupled with the known high sensitivity and reproducibility of the TT seem to suggest that sildenafil is haemodynamically safer than is generally believed even when added on top of vasoactive treatment. These findings should be put into perspective against the growing wealth of evidence that PDE5 inhibitors may have therapeutic potential for a number of CV conditions.
Keywords: Erectile disfunction, sildenafil, orthostatic hypotension, drug safety, cardiovascular disease, Tilt Test, Plethysmography, PDE5 inhibitors
Current Drug Safety
Title: Limited Hypotensive Effect of Sildenafil in a High-Risk Population: A Preliminary Report
Volume: 6 Issue: 4
Author(s): M. M. Ciulla, P. Nicolini, C. Benfenati, C. Vecchiato, G. Acquistapace, G. L. Perrucci and F. Magrini
Affiliation:
Keywords: Erectile disfunction, sildenafil, orthostatic hypotension, drug safety, cardiovascular disease, Tilt Test, Plethysmography, PDE5 inhibitors
Abstract: Erectile dysfunction (ED) is often associated with cardiovascular disease (CVD) and the risk of sildenafilinduced orthostatic hypotension (OH) in subjects with CVD is a matter of concern. We describe our experience in using the tilt test (TT) with continuous plethysmography to evaluate the occurrence of OH in patients with CVD and ED after a test dose of sildenafil. When sildenafil was added on top of their usual pharmacological treatment two patients out of 32 (6.2%) developed asymptomatic OH, with a maximum blood pressure fall of 40/20 mm Hg. The low prevalence and modest clinical relevance of OH in our high-risk population coupled with the known high sensitivity and reproducibility of the TT seem to suggest that sildenafil is haemodynamically safer than is generally believed even when added on top of vasoactive treatment. These findings should be put into perspective against the growing wealth of evidence that PDE5 inhibitors may have therapeutic potential for a number of CV conditions.
Export Options
About this article
Cite this article as:
M. Ciulla M., Nicolini P., Benfenati C., Vecchiato C., Acquistapace G., L. Perrucci G. and Magrini F., Limited Hypotensive Effect of Sildenafil in a High-Risk Population: A Preliminary Report, Current Drug Safety 2011; 6 (4) . https://dx.doi.org/10.2174/157488611798280898
DOI https://dx.doi.org/10.2174/157488611798280898 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Role of Transforming Growth Factor β1 in the Regulation of Blood Pressure
Current Hypertension Reviews Functional Neuroanatomy of the Noradrenergic Locus Coeruleus: Its Roles in the Regulation of Arousal and Autonomic Function Part I: Principles of Functional Organisation
Current Neuropharmacology Chronic Kidney Disease and Thrombosis
Current Pediatric Reviews Serum Cystatin C-A Useful Endogenous Marker of Renal Function in Intensive Care Unit Patients at Risk for or with Acute Renal Failure?
Current Medicinal Chemistry Imidazole Scaffold Based Compounds in the Development of Therapeutic Drugs
Current Topics in Medicinal Chemistry Heart Failure in South America
Current Cardiology Reviews Altered CYP Expression and Function in Response to Dietary Factors: Potential Roles in Disease Pathogenesis
Current Drug Metabolism Oxytocin in the Heart Regeneration
Recent Patents on Cardiovascular Drug Discovery Traditional and Alternative Therapies for Refractory Angina
Current Pharmaceutical Design Disulfiram: An Old Therapeutic with New Applications
CNS & Neurological Disorders - Drug Targets Milestones in Antihypertensive Drug Treatment
Current Pharmaceutical Design Overcoming Drug Resistance by Enhancing Apoptosis of Tumor Cells
Current Cancer Drug Targets Targeting B Cells in SLE: The Experience with Rituximab Treatment (Anti-CD20)
Endocrine, Metabolic & Immune Disorders - Drug Targets Turnover Studies on Cardiac Natriuretic Peptides: Methodological,Pathophysiological and Therapeutical Considerations.
Current Drug Metabolism Occurrence and Biological Activities of Eremophilane-type Sesquiterpenes
Mini-Reviews in Medicinal Chemistry Digital Ulcers in Systemic Sclerosis – How to Manage in 2013?
Current Rheumatology Reviews Atrial Fibrillation in Acute St-Elevation Myocardial Infarction: Clinical and Prognostic Features
Current Cardiology Reviews Multicenter Randomized Controlled Trial for the Treatment of Ulcerative Colitis with a Leukocytapheresis Column
Current Pharmaceutical Design Bleeding and Acute Coronary Syndromes: Defining, Predicting, and Managing Risk and Outcomes
Current Drug Targets Studies on Novel Pyridine and 2-pyridone Derivatives of N-arylpiperazine as α-adrenoceptor Ligands
Medicinal Chemistry